Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 75
- Registration Number
- NCT05497804
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05495620
Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Jiangxi Provincial People's Hopital
- Target Recruit Count
- 10
- Registration Number
- NCT05488327
- Locations
- 🇨🇳
Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Irene Ghobrial, MD
- Target Recruit Count
- 52
- Registration Number
- NCT05469893
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05438043
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Barnes-jewish Hospital, Saint Louis, Missouri, United States
🇧🇪ZNA Stuivenberg, Antwerpen, Belgium
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT05429268
- Locations
- 🇧🇬
Medical University Plovdiv, Plovdiv, Bulgaria
🇧🇬Acibadem Cityclinica Mhat Tokuda, Sofia, Bulgaria
🇧🇬Umhat Alexandrovska Sofia, Sofia, Bulgaria
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Xia Zhongjun
- Target Recruit Count
- 42
- Registration Number
- NCT05422027
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China,, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 500
- Registration Number
- NCT05409066
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences /ID# 227198, Little Rock, Arkansas, United States
🇺🇸Beverly Hills Cancer Center /ID# 231535, Beverly Hills, California, United States
🇺🇸Valkyrie Clinical Trials /ID# 268502, Los Angeles, California, United States
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 230
- Registration Number
- NCT05371093
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇺🇸UC Irvine Health, Orange, California, United States
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 35
- Registration Number
- NCT05351593
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.